When considering valuation metrics, the price-to-earnings (P/E) ratio has always been the obvious choice as calculations based on earnings are easy and come in handy. However, in the case of companies ...

Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from ...

Most appealing to long-term investors is that Pfizer stock is trading near its decade-long low in terms of price to forward earnings at 7.7X and well below the high of 20.1X during this period. PFE ...

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable ...

U.S. stock futures point slightly higher following mixed trading in the previous session, with a bevy of corporate earnings and economic data in focus. U.S. President Donald Trump is set to soften his ...

Analysts expect the New York-based company to report quarterly earnings at 68 cents per share, down from 82 cents per share ...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings tomorrow before market hours. Here’s what you need ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Pfizer's robust product pipeline and consistent R&D investments position it well for future growth. See why I rate PFE stock ...

Pfizer has declared a quarterly dividend of $0.43 per share for Q2 2025, marking its 346th consecutive quarter of payouts.

In the closing of the recent trading day, Pfizer (PFE) stood at $22.36, denoting a -0.78% change from the preceding trading day.